Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01535040 · ClinicalTrials.gov registry record · Phase 2
Memantine Hydrochloride in Helping Cancer Survivors Stop Smoking
A Phase 2 study, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 130
- Enrollment target
NCT01535040 is a Phase 2 study that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 130 participants.
The verdict
NCT01535040, a Phase 2 study, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 130 participants
- Enrollment target
Study Summary
RATIONALE: Memantine hydrochloride may help people stop smoking by decreasing the symptoms of nicotine withdrawal. PURPOSE: This randomized, pilot phase II trial studies how effective memantine hydrochloride works compared to placebo in helping cancer survivors stop smoking.
Interventions
- DRUG placebo
- DRUG memantine hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2012-08-01 |
| Est. Completion | 2014-02-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01535040
The ClinicalTrials.gov registry entry for NCT01535040 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT01535040 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01535040 about?
NCT01535040 is a clinical study titled "Memantine Hydrochloride in Helping Cancer Survivors Stop Smoking". RATIONALE: Memantine hydrochloride may help people stop smoking by decreasing the symptoms of nicotine withdrawal. PURPOSE: This randomized, pilot phase II trial studies how effective memantine hydrochloride works compared to placebo in helping cancer survivors stop smoking.
What is the current status of trial NCT01535040?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 130 participants. The study started on 2012-08-01. Estimated completion is 2014-02-01.
What interventions are being tested in trial NCT01535040?
The interventions under investigation include: placebo (DRUG), memantine hydrochloride (DRUG).
Who is sponsoring clinical trial NCT01535040?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.